Discrepancies between the asthma control test and quality of life scores among biologic- and nonbiologic-treated asthma patients
Allergology International · 2026
DOI: 10.1016/j.alit.2025.11.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergology International, 2026. Verfasst von Hironobu Sunadome und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Respiratory Medi…. Hauptthemen laut MEDLINE: Quality of Life, Asthma, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: In the era of asthma remission, quality of life (QOL) in daily activities is increasingly valued in addition to exacerbation control. However, the value of the Asthma Control Test (ACT) for assessing QOL remains unclear. This study compared the use of the ACT with the Asthma Quality of Life Questionnaire (AQLQ), with a focus on activity limitations. METHODS: We first analyzed biologic-treated asthma patients who were attending our institution and assessed the relationship between stable-phase ACT scores and AQLQ scores (including both overall scores and domain-specific scores). Receiver operating characteristic (ROC) curves were analyzed to identify the optimal ACT threshold for predicting favorable AQLQ scores. The findings were subsequently validated in a nonbiologic-treated group. RESULTS: Among biologic-treated patients (n = 69), the median ACT and AQLQ scores were 22 (IQR: 18-25) and 5.5 (IQR: 4.7-6.4), respectively. Discrepancies between the ACT and AQLQ were most evident in the activity limitation domain. Half of the patients with well-controlled ACT scores (≥20) reported difficulty with high-intensity exercise and avoiding environmental triggers, regardless of asthma duration. ROC curve analysis revealed that an ACT score ≥23 predicted favorable AQLQ activity limitation scores (≥6) (AUC: 0.83; sensitivity: 86 %; specificity: 76 %). Favorable scores were more commonly observed in the ACT ≥23 group than in the 20-22 group (p < 0.01). Similar findings were observed in the nonbiologic group (n = 123). CONCLUSIONS: A cutoff score of ≥23 for the ACT may better reflect patient-perceived QOL than the conventional cutoff score of 20.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Elec…
- Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Zitieren
APA
Sunadome, H., Matsumoto, H., Hayashi, Y., Maetani, T., Terada, S., Nishi, K., Shiraishi, Y., Tanabe, N., Sato, A., Sato, S., & Hirai, T. (2026). Discrepancies between the asthma control test and quality of life scores among biologic- and nonbiologic-treated asthma patients. Allergology International. https://doi.org/10.1016/j.alit.2025.11.003
Vancouver
Sunadome H, Matsumoto H, Hayashi Y, Maetani T, Terada S, Nishi K, et al. Discrepancies between the asthma control test and quality of life scores among biologic- and nonbiologic-treated asthma patients. Allergology International. 2026. doi:10.1016/j.alit.2025.11.003
BibTeX
@article{Sunadome2026,
author = {Sunadome, Hironobu and Matsumoto, Hisako and Hayashi, Yusuke and Maetani, Tomoki and Terada, Satoru and Nishi, Kenta and Shiraishi, Yusuke and Tanabe, Naoya and Sato, Atsuyasu and Sato, Susumu and Hirai, Toyohiro},
title = {Discrepancies between the asthma control test and quality of life scores among biologic- and nonbiologic-treated asthma patients},
journal = {Allergology International},
year = {2026},
doi = {10.1016/j.alit.2025.11.003}
}
EUVIMED